Advertisement
Advertisement
U.S. Markets close in 2 hrs 18 mins
Advertisement
Advertisement
Advertisement
Advertisement

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9200+0.0600 (+3.23%)
As of 12:17PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8600
Open1.9400
Bid1.9000 x 900
Ask1.9100 x 900
Day's Range1.9000 - 1.9400
52 Week Range1.6700 - 8.1970
Volume12,221
Avg. Volume174,985
Market Cap36.127M
Beta (5Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.2960
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
  • GlobeNewswire

    EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference

    – New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis DURHAM, N.C. and COPENHAGEN, Denmark, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal study of WYNZO

  • Zacks Small Cap Research

    NOVN: EPI Revenue Trends Are Strong

    By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Second Quarter 2022 Results On August 11, 2022, Novan Inc. (NASDAQ:NOVN) reported second quarter financial and operational results in a press release and the filing of Form 10-Q . A conference call and webcast were subsequently held to update investors on recent developments. The call highlighted the performance of the EPI

  • GlobeNewswire

    Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    – Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the second quarter ended June 30, 2022 and provided a corporate update. The C

Advertisement
Advertisement